Apimeds Pharmaceuticals US, Inc. (APUS) — Financial Flexibility Index
Apimeds Pharmaceuticals US, Inc. (APUS) has a Financial Flexibility Index of -1.56x as of September 2025. Free cash flow of $-1.70 Million (operating CF $-1.73 Million minus capex $22.54K) represents -2% of total liabilities ($1.09 Million). Also explore APUS year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Apimeds Pharmaceuticals US, Inc. Financial Flexibility Index (2021–2024)
Historical Financial Flexibility Index trend for Apimeds Pharmaceuticals US, Inc. across 4 annual periods. See APUS net asset quality score to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for Apimeds Pharmaceuticals US, Inc. (2021–2024)
Year-by-year free cash flow to debt coverage for Apimeds Pharmaceuticals US, Inc.. For the full company profile including market capitalisation, see APUS market cap.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.53x | $-733.53K | $-733.53K | $1.37 Million | ▲ +66.7% |
| 2023 | -1.61x | $-627.79K | $-627.79K | $390.20K | ▼ -158.4% |
| 2022 | -0.62x | $-448.17K | $-448.17K | $719.78K | ▲ +68.9% |
| 2021 | -2.00x | $-823.11K | $-823.11K | $410.65K | — |